SunRock develops therapeutical antibodies targeted at the Chemokine Receptor 9, CCR9, a new therapeutic target whose over-expression is correlated with the invading capacity of the Acute Lymphoblastic Leukemia of T Lymphocites, the Chronic Lymphoblastic Leukemia of T Lymphocites and solid tumors such as the ovary cancer, prostate cancer, breast cancer and melanoma.